Jefferies Financial Group Inc. Mirati Therapeutics, Inc. Call Options Transaction History

Jefferies Financial Group Inc.

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 13, 2024	BUY	$41.99 - $62.38 $1.31 Million - $1.95 Million	31,200 Added 98.11%	63,000 $3.7 Million
Q3 2023 Nov 14, 2023	BUY	$27.8 - $45.35 $633,840 - $1.03 Million	22,800 Added 253.33%	31,800 $1.39 Million
Q2 2023 Aug 14, 2023	BUY	$36.13 - $49.49 $162,585 - $222,705	4,500 Added 100.0%	9,000 $325,000
Q1 2023 May 15, 2023	SELL	$36.54 - $54.26 $200,970 - $298,430	-5,500 Reduced 55.0%	4,500 $167,000
Q4 2022 Sep 21, 2023	BUY	$41.27 - $98.62 $41,270 - $98,620	1,000 Added 11.11%	10,000 $453,000
Q4 2022 Feb 14, 2023	BUY	$41.27 - $98.62 $412,700 - $986,200	10,000 New	10,000 $453,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Jefferies Financial Group Inc., based on Form 13F filings with the SEC.

Stay updated on Jefferies Financial Group Inc. with notifications on news.